Recruiting × Interventional × Nasopharyngeal Carcinoma × Clear all IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
Phase 3 Recruiting
380 enrolled
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Phase 2 Recruiting
156 enrolled
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Phase 2 Recruiting
50 enrolled
Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
Phase 2 Recruiting
243 enrolled
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
Phase 3 Recruiting
266 enrolled
Proton Therapy for Recurrent Nasopharyngeal Carcinoma
Phase NA Recruiting
52 enrolled
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Phase 3 Recruiting
593 enrolled
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Phase 1 Recruiting
40 enrolled
Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma
Phase 3 Recruiting
180 enrolled
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
Phase 2 Recruiting
30 enrolled
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Phase 2 Recruiting
28 enrolled
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
Phase 2 Recruiting
24 enrolled
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Phase 2 Recruiting
98 enrolled
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
Phase 2 Recruiting
41 enrolled
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Phase 2 Recruiting
570 enrolled
Magic-C002
Phase 3 Recruiting
446 enrolled
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
Phase 3 Recruiting
300 enrolled
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
Phase 3 Recruiting
456 enrolled
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
Phase 3 Recruiting
346 enrolled
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Phase NA Recruiting
590 enrolled
INCIPT-NPC
Phase 3 Recruiting
462 enrolled
Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer
Phase 3 Recruiting
166 enrolled
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Phase 1/2 Recruiting
202 enrolled
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
Phase 2 Recruiting
70 enrolled
Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
Phase 3 Recruiting
550 enrolled
NACASOR
Phase 1/2 Recruiting
10 enrolled
Light
Phase 2 Recruiting
26 enrolled
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Phase 2 Recruiting
121 enrolled
Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 2 Recruiting
30 enrolled
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Phase 2 Recruiting
208 enrolled
Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
Phase 2 Recruiting
109 enrolled
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
Phase 2 Recruiting
76 enrolled
Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
Phase 2 Recruiting
40 enrolled
Screening for Early Diagnosis of Nose Cancer
Phase NA Recruiting
20,000 enrolled
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
Phase 3 Recruiting
154 enrolled
Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma
Phase 3 Recruiting
386 enrolled
TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
Phase 2 Recruiting
70 enrolled
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Phase 1/2 Recruiting
148 enrolled
Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
Phase 2 Recruiting
69 enrolled
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
Phase NA Recruiting
66 enrolled
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Phase NA Recruiting
118 enrolled
PROTECT-NPC
Phase 3 Recruiting
474 enrolled
Nituzumab (Taixinsheng ®) A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma
Phase 2 Recruiting
170 enrolled
Metastatic Nasopharyngeal Carcinoma
Phase 1 Recruiting
47 enrolled
Navigation
Phase 3 Recruiting
466 enrolled
Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas
Phase NA Recruiting
68,649 enrolled
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
Phase 2 Recruiting
47 enrolled
Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
Phase NA Recruiting
30 enrolled
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3 Recruiting
400 enrolled
PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
Phase 3 Recruiting
212 enrolled